<DOC>
	<DOC>NCT00543595</DOC>
	<brief_summary>This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).</brief_summary>
	<brief_title>MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Have Type 2 Diabetes 18 to 65 years of age History of Type 1 Diabetes Mellitus Have been treated with insulin in the past 8 weeks On a weight loss program and have ongoing weight loss Taking weight loss medication Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery Have taken another investigational drug in the last 8 weeks Have active liver disease Have a history of major surgery involving gastric or intestinal bypass</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>